Accessing Fatty Acylated Peptides: Fmoc-Lys(Palmitoyl)-OH, Fmoc-Lys(Alloc)-OH & Fmoc-Lys(ivDDe)-OH

For researchers looking for a convenient way to increase the lipophilicity of their peptide, you can consider using different lengths of fatty acyl groups coupled on the N-terminus or on a side chain derivatized Lys residue in the primary sequence or at the C-terminus. We now offer a convenient way to make these products by providing our newest derivative Fmoc-Lys(palmitoyl)-OH for your synthesis needs. If you choose to vary the length of the acyl moiety, this is conveniently achieved by using an orthogonally protected Lys derivative such as our Fmoc-Lys(Alloc)-OH or Fmoc-Lys(ivDde)-OH. By maintaining an α amino protecting group at the completion of synthesis, removal of the orthogonal group can be achieved with tetrakis-triphenylphosphine Pd (0) or 2% hydrazine in DMF, respectively for Alloc and ivDde, and a longer or shorter acyl group can be coupled to the free epsilon amino group.

Custom Peptide Synthesis , Tools for Peptide Synthesis

Dr. Michael W. Pennington

See all articles from Dr. Michael W. Pennington

Dr. Michael Pennington joined Peptides International in December 2010 as Chief Technology Officer. On January 1, 2013, Dr. Pennington's role became that of President and Chief Executive Officer. After doctoral research at University of Florida, he joined the pharmaceutical industry in the Department of Biotechnology at Schering-Plough. He joined Bachem Biosciences in King of Prussia, PA as a Principle Scientist in the Peptide Chemistry department. Dr. Pennington served as the Group Director for Bachem Biosciences before being appointed as President and C.O.O., a positioned he maintained from 2000 – 2010. He built and directed an internationally recognized peptide chemistry team focused on producing complex peptides and toxins. Dr. Pennington was a member of Bachem Forschungausschuss, the International Research and Development from 2000 – 2010. He has extensive collaborations with both industrial and academic scientists and maintains an extramurally funded research program on several peptide toxins. He is a founder of Airmid Inc., a biotech venture company dedicated to advancing two of his discoveries into clinical development for autoimmune diseases. Dr. Pennington has been awarded four patents and over 85 peer reviewed scientific articles, and serves as an editor of International Journal of Peptide Research and Therapeutics and Current Peptide and Protein Letters. He holds a Bachelor of Chemistry degree from the University of North Carolina at Chapel Hill and a Ph.D. from University of Florida at Gainesville.